Jula Inrig Sells 1,018 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 1,018 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $42.61, for a total value of $43,376.98. Following the sale, the insider owned 111,473 shares of the company’s stock, valued at $4,749,864.53. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total value of $302,524.95.
• On Wednesday, February 4th, Jula Inrig sold 1,779 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.21, for a total value of $57,301.59.
• On Tuesday, February 3rd, Jula Inrig sold 6,956 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $223,426.72.

Travere Therapeutics Stock Down 3.4%

NASDAQ TVTX opened at $39.54 on Friday. The business has a fifty day moving average price of $29.77 and a two-hundred day moving average price of $31.42. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $43.31. The stock has a market capitalization of $3.65 billion, a PE ratio of -131.80 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen downgraded shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Guggenheim upped their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Travere Therapeutics by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after purchasing an additional 6,831 shares during the period. Norges Bank acquired a new stake in Travere Therapeutics in the second quarter valued at $1,051,000. First Trust Advisors LP acquired a new stake in Travere Therapeutics in the second quarter valued at $3,538,000. Cresset Asset Management LLC increased its holdings in Travere Therapeutics by 26.5% in the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock valued at $427,000 after purchasing an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd increased its holdings in Travere Therapeutics by 106.2% in the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock valued at $8,941,000 after purchasing an additional 311,137 shares during the period.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, materially expanding Travere’s rare‑kidney franchise and adding an estimated ~30,000 U.S. patients to the addressable market — the core reason for the earlier, large share price gain. Filspari approval article
• Positive Sentiment: Market reaction and analyst upgrades lifted sentiment and targets (examples: Canaccord, Guggenheim, Piper Sandler, HC Wainwright), reinforcing a re‑rating narrative and supporting higher medium‑term revenue expectations for Filspari. Guggenheim note
• Neutral Sentiment: Trading activity is elevated and options volumes spiked around the approval — this amplifies short‑term moves (both up and down) and suggests greater volatility while the market digests label details and early commercialization assumptions. Options activity report
• Neutral Sentiment: Company commentary and coverage (conference/transcript writeups, health press) are clarifying the label and launch plans, but concrete revenue/volume reads are not yet available — useful for modeling but not definitive. Company discussion
• Negative Sentiment: Multiple insiders (CEO, directors, CFO, other executives) sold material blocks of shares over the last two trading days — most sales were executed under pre‑arranged Rule 10b5‑1 plans or to cover taxes related to vesting, but the scale of selling can fuel near‑term downward pressure and signal profit‑taking after the approval‑driven rally. Example SEC filing for CEO sale. CEO Form 4
• Negative Sentiment: Some analysts warn that estimate‑revision trends and elevated expectations could limit near‑term upside — the stock may consolidate or pull back as investors re‑rate forward revenue assumptions. Zacks caution

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.